EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
EyePoint Pharmaceuticals Inc
Depreciation & Amortization
EyePoint Pharmaceuticals Inc
Depreciation & Amortization Peer Comparison
Competitive Depreciation & Amortization Analysis
Latest Figures & CAGR of Competitors
Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
|
Depreciation & Amortization
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Depreciation & Amortization
-$9.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-183%
|
CAGR 10-Years
-70%
|
|
Pfizer Inc
NYSE:PFE
|
Depreciation & Amortization
-$4.9B
|
CAGR 3-Years
-78%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
Merck & Co Inc
NYSE:MRK
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Eli Lilly and Co
NYSE:LLY
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is EyePoint Pharmaceuticals Inc's Depreciation & Amortization?
Depreciation & Amortization
0
USD
Based on the financial report for Dec 31, 2023, EyePoint Pharmaceuticals Inc's Depreciation & Amortization amounts to 0 USD.